GlassScriptPhysician profile
Anish Chopra
NPI 1962616409
$9,269.12
in general payments reported to CMS, 2019-2025
40 companies · $2,332 in 2025
The $2,332 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $401 · 2021: $1,434 · 2022: $1,764 · 2023: $1,392 · 2024: $1,078 · 2025: $2,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,741 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,741.17 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,749.69 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Nestle Healthcare Nutrition INC. | $1,060.80 | 2021-2023 | |
| Olympus Corporation of The Americas | $799.09 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $692.53 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $530.56 | 2020-2024 | Xifaxan |
| Janssen Biotech, INC. | $518.32 | 2019-2025 | Tremfya, Stelara, Remicade |
| Inari Medical, INC. | $336.45 | 2021-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Madrigal Pharmaceuticals | $329.87 | 2025 | Rezdiffra |
| Lilly USA, LLC | $244.15 | 2024-2025 | Jardiance, Omvoh |
| Gilead Sciences, INC. | $241.20 | 2021-2025 | |
| Ardelyx, INC. | $207.10 | 2023-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $181.97 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $175.55 | 2020-2022 | |
| Neuraxis, INC. | $167.40 | 2025 | |
| Merck Sharp & Dohme LLC | $152.20 | 2020-2024 | Dificid |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $140.36 | 2024-2025 | Voquezna |
| Genzyme Corporation | $139.87 | 2022-2025 | |
| Braintree Laboratories, INC. | $128.54 | 2020-2025 | Sutab, Suflave |
| Celgene Corporation | $123.24 | 2021-2023 | Zeposia |
| Sirtex Medical INC | $122.81 | 2025 | Sir-Spheres Microspheres |
| Lexicon Pharmaceuticals, INC. | $122.80 | 2024 | Inpefa |
| Pfizer INC. | $116.07 | 2022-2025 | |
| Redhill Biopharma INC. | $90.58 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $87.21 | 2024-2025 | Zenpep |
| Medtronic, INC. | $82.26 | 2022-2025 | Bravo |
| Janssen Pharmaceuticals, INC | $78.86 | 2022 | |
| Qol Medical, LLC | $75.60 | 2023-2025 | Sucraid, Sucraid |
| Conmed Corporation | $73.29 | 2021 | |
| Ironwood Pharmaceuticals, INC | $71.40 | 2022-2024 | Linzess |
| Vivus LLC | $65.44 | 2022-2025 | Pancreaze |
| Axsome Therapeutics, INC. | $58.56 | 2023 | Auvelity |
| Ferring Pharmaceuticals INC. | $49.11 | 2019-2025 | Rebyota |
| Alfasigma USA, INC. | $44.68 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.93 | 2023 | Cyltezo |
| Organon LLC | $37.21 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $32.96 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $31.10 | 2020-2022 | |
| Stryker Corporation | $28.77 | 2022 | |
| Celltrion USA INC. | $26.62 | 2025 | Vegzelma |
| Olympus America INC. | $14.97 | 2024 | Visiglide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anish Chopra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.